JP2012521366A5 - - Google Patents

Download PDF

Info

Publication number
JP2012521366A5
JP2012521366A5 JP2012501089A JP2012501089A JP2012521366A5 JP 2012521366 A5 JP2012521366 A5 JP 2012521366A5 JP 2012501089 A JP2012501089 A JP 2012501089A JP 2012501089 A JP2012501089 A JP 2012501089A JP 2012521366 A5 JP2012521366 A5 JP 2012521366A5
Authority
JP
Japan
Prior art keywords
seq
purified
use according
klk1
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012501089A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012521366A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2010/000413 external-priority patent/WO2010108262A1/en
Publication of JP2012521366A publication Critical patent/JP2012521366A/ja
Publication of JP2012521366A5 publication Critical patent/JP2012521366A5/ja
Pending legal-status Critical Current

Links

JP2012501089A 2009-03-25 2010-03-25 膵臓β細胞機能不全の治療のための組織カリクレイン Pending JP2012521366A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16317309P 2009-03-25 2009-03-25
US61/163,173 2009-03-25
PCT/CA2010/000413 WO2010108262A1 (en) 2009-03-25 2010-03-25 TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC β-CELL DYSFUNCTION

Publications (2)

Publication Number Publication Date
JP2012521366A JP2012521366A (ja) 2012-09-13
JP2012521366A5 true JP2012521366A5 (https=) 2013-05-09

Family

ID=42780097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012501089A Pending JP2012521366A (ja) 2009-03-25 2010-03-25 膵臓β細胞機能不全の治療のための組織カリクレイン

Country Status (8)

Country Link
US (1) US20120070425A1 (https=)
EP (1) EP2411042A4 (https=)
JP (1) JP2012521366A (https=)
CN (1) CN102438648A (https=)
AU (1) AU2010228068A1 (https=)
CA (1) CA2756801A1 (https=)
NZ (1) NZ595364A (https=)
WO (1) WO2010108262A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2182978A4 (en) 2007-07-20 2012-03-21 Sanomune Inc TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN
EP2720703A4 (en) * 2011-06-17 2015-07-22 Univ Johns Hopkins METHOD FOR INCREASING INSULIN SENSITIVITY AND TREATING DIABETES
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
EP2854841B1 (en) 2012-06-04 2017-02-22 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
CN109498815B (zh) * 2013-12-30 2022-07-22 江苏众红生物工程创药研究院有限公司 重组人激肽释放酶的化学修饰物及其应用
CN110446501A (zh) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 组织激肽释放酶1的剂型
CN112481268B (zh) * 2021-01-25 2024-01-30 河南大学 一种棉花启动子PGhPGF及其重组载体和应用
CN116135973A (zh) * 2021-11-16 2023-05-19 江苏众红生物工程创药研究院有限公司 低糖基化修饰的激肽原酶及其聚乙二醇修饰物和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
JP2002516261A (ja) * 1998-05-22 2002-06-04 エンターメッド インコーポレイテッド セリンプロテアーゼを利用して内皮細胞増殖を阻害し血管新生を調節するための組成物と方法
CN1228447C (zh) * 2001-02-20 2005-11-23 深圳市人民医院 一种含有人胰腺组织激肽释放酶成熟蛋白基因的重组表达载体
CN100338212C (zh) * 2003-01-29 2007-09-19 中国科学院大连化学物理研究所 人组织激肽释放酶的微囊化细胞及其微囊化方法和应用
CA2575791A1 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
CN101094869A (zh) * 2004-08-03 2007-12-26 戴埃克斯有限公司 Hk1结合蛋白
CA2659012A1 (en) * 2006-07-26 2008-01-31 Diamedica Inc. Methods of diagnosis and treatment for metabolic disorders
JP5322935B2 (ja) * 2006-07-31 2013-10-23 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬
CN101134953B (zh) * 2007-07-02 2011-02-09 广东天普生化医药股份有限公司 重组人胰激肽原酶
CN101255438B (zh) * 2008-04-11 2012-01-25 深圳大学 表达人组织激肽释放酶的转基因莱茵衣藻的构建方法

Similar Documents

Publication Publication Date Title
JP2012521366A5 (https=)
NZ627372A (en) Clostridium histolyticum enzymes and methods for the use thereof
RU2013151875A (ru) Модифицированная кислая альфа глюкозидаза с ускоренным процессингом
JP2014513952A5 (https=)
JP2012176978A5 (https=)
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
NZ597306A (en) Mesenchymal stem cell differentiation
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
JP2012530504A5 (https=)
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
IN2012DN03368A (https=)
NZ596823A (en) Swine influenza hemagglutinin variants
JP2014506450A5 (https=)
NZ600583A (en) Visfatin therapeutic agents for the treatment of acne and other conditions
JP2014529399A5 (https=)
NZ610620A (en) Inhibitors of apoptosis and uses thereof
JP2017511133A (ja) 新規の方法、ポリペプチド、及びその使用
NZ703514A (en) Fviii peptides for immune tolerance induction and immunodiagnostics
NZ614557A (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
RU2008102738A (ru) Протеазы для фармацевтического применения
WO2010086867A3 (en) Peptides, pharmaceutical compositions comprising same and uses thereof